The concern of generic challenges has long loomed above copyright’s iconic drug, PDE5 Inhibitor, sparking questions about the outlook of similar drug portfolios. While early years saw substantial returns, the exclusivity end has created the door for cheaper copies, potentially diminishing profitability and creating a significant risk for sharehol